Molecular Imaging Biomarkers in Dementia: Amyloid and Tau PET Imaging Aids Evaluation of Patients Suspected of Having Alzheimer Disease or Other Dementias

Overview

Journal Pract Neurol (Fort Wash Pa)

Date 2021 Aug 30

PMID 34456638

Citations 1

Authors

Brad Dickerson

Alireza Atri

Affiliations

Soon will be listed here.

Citing Articles

Thai Guideline for Nuclear Medicine Investigations of Neurocognitive Disorders: Nuclear Medicine Society of Thailand, the Neurological Society of Thailand, and Thai Medical Physicist Society Collaboration.

Kaewchur T, Thientunyakit T, Chamroonrat W, Khiewvan B, Kiatkittikul P, Wongsurawat N Diagnostics (Basel). 2024; 14(22).

PMID: 39594140 PMC: 11592784. DOI: 10.3390/diagnostics14222474.

Combining Blood-Based Biomarkers and Structural MRI Measurements to Distinguish Persons with and without Significant Amyloid Plaques.

Chen Y, Su Y, Wu J, Chen K, Atri A, Caselli R J Alzheimers Dis. 2024; 98(4):1415-1426.

PMID: 38578889 PMC: 11789004. DOI: 10.3233/JAD-231162.

References

Josephs K, MacKenzie I, Frosch M, Bigio E, Neumann M, Arai T . LATE to the PART-y. Brain. 2019; 142(9):e47. PMC: 6736234. DOI: 10.1093/brain/awz224. View

Fleisher A, Pontecorvo M, Devous Sr M, Lu M, Arora A, Truocchio S . Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. JAMA Neurol. 2020; 77(7):829-839. PMC: 7186920. DOI: 10.1001/jamaneurol.2020.0528. View

Schwarz A, Yu P, Miller B, Shcherbinin S, Dickson J, Navitsky M . Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Brain. 2016; 139(Pt 5):1539-50. DOI: 10.1093/brain/aww023. View

Shaw L, Arias J, Blennow K, Galasko D, Molinuevo J, Salloway S . Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease. Alzheimers Dement. 2018; 14(11):1505-1521. PMC: 10013957. DOI: 10.1016/j.jalz.2018.07.220. View

Schneider J, Nelson P . Reply: Limbic-predominant age-related TDP-43 encephalopathy (LATE). Brain. 2019; 142(8):e43. DOI: 10.1093/brain/awz186. View

Schonhaut D, McMillan C, Spina S, Dickerson B, Siderowf A, Devous Sr M . F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study. Ann Neurol. 2017; 82(4):622-634. PMC: 5665658. DOI: 10.1002/ana.25060. View

Bergeron D, Gorno-Tempini M, Rabinovici G, Santos-Santos M, Seeley W, Miller B . Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia. Ann Neurol. 2018; 84(5):729-740. PMC: 6354051. DOI: 10.1002/ana.25333. View

Pontecorvo M, Devous Sr M, Navitsky M, Lu M, Salloway S, Schaerf F . Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain. 2017; 140(3):748-763. PMC: 5382945. DOI: 10.1093/brain/aww334. View

Marquie M, Siao Tick Chong M, Anton-Fernandez A, Verwer E, Saez-Calveras N, Meltzer A . [F-18]-AV-1451 binding correlates with postmortem neurofibrillary tangle Braak staging. Acta Neuropathol. 2017; 134(4):619-628. PMC: 5772971. DOI: 10.1007/s00401-017-1740-8. View

10.

Crary J, Trojanowski J, Schneider J, Abisambra J, Abner E, Alafuzoff I . Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 2014; 128(6):755-66. PMC: 4257842. DOI: 10.1007/s00401-014-1349-0. View

11.

Markesbery W, Schmitt F, Kryscio R, Davis D, Smith C, Wekstein D . Neuropathologic substrate of mild cognitive impairment. Arch Neurol. 2006; 63(1):38-46. DOI: 10.1001/archneur.63.1.38. View

12.

Cho H, Choi J, Hwang M, Kim Y, Lee H, Lee H . In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann Neurol. 2016; 80(2):247-58. DOI: 10.1002/ana.24711. View

13.

Sabri O, Sabbagh M, Seibyl J, Barthel H, Akatsu H, Ouchi Y . Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study. Alzheimers Dement. 2015; 11(8):964-74. DOI: 10.1016/j.jalz.2015.02.004. View

14.

Makaretz S, Quimby M, Collins J, Makris N, McGinnis S, Schultz A . Flortaucipir tau PET imaging in semantic variant primary progressive aphasia. J Neurol Neurosurg Psychiatry. 2017; 89(10):1024-1031. PMC: 5964045. DOI: 10.1136/jnnp-2017-316409. View

15.

Rabinovici G, Gatsonis C, Apgar C, Chaudhary K, Gareen I, Hanna L . Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. JAMA. 2019; 321(13):1286-1294. PMC: 6450276. DOI: 10.1001/jama.2019.2000. View

16.

Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View

17.

Ossenkoppele R, Rabinovici G, Smith R, Cho H, Scholl M, Strandberg O . Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA. 2018; 320(11):1151-1162. PMC: 6233630. DOI: 10.1001/jama.2018.12917. View

18.

Mesulam M, Dickerson B, Sherman J, Hochberg D, Gonzalez R, Johnson K . Case 1-2017. A 70-Year-Old Woman with Gradually Progressive Loss of Language. N Engl J Med. 2017; 376(2):158-167. PMC: 5264551. DOI: 10.1056/NEJMcpc1613459. View

19.

Atri A . Imaging of neurodegenerative cognitive and behavioral disorders: practical considerations for dementia clinical practice. Handb Clin Neurol. 2016; 136:971-84. DOI: 10.1016/B978-0-444-53486-6.00050-8. View

20.

Brendel M, Barthel H, van Eimeren T, Marek K, Beyer L, Song M . Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy. JAMA Neurol. 2020; 77(11):1408-1419. PMC: 7341407. DOI: 10.1001/jamaneurol.2020.2526. View